Is Wegovy Bad for Your Heart? What the Evidence Shows

What a trial of 17,000 people actually found about semaglutide and the heart

The SELECT trial is the clearest answer to this question. It recruited 17,604 adults who were living with obesity or overweight and had already experienced a cardiovascular event (a heart attack, stroke, or established arterial disease) but did not have type 2 diabetes. Over a median of around 34 months, participants receiving semaglutide 2.4mg weekly were about 20% less likely to suffer a further major cardiovascular event than those on placebo. The result was statistically robust and reached across subgroups.

That evidence led the MHRA to approve a specific cardiovascular-risk indication for Wegovy, separate from its weight-management licence. The NHS semaglutide medicines page acknowledges this broader role. So the short answer to whether Wegovy is bad for your heart is: no, not in the population studied — and for people with existing cardiovascular disease, it may offer meaningful protection.

It is worth being precise about what the trial measured. SELECT was designed for people with prior cardiovascular disease, not the general population. The cardiovascular benefit observed there cannot simply be assumed to apply identically to someone with no cardiac history. That distinction matters for how you weigh the evidence personally.

The heart-rate question people actually worry about

A question our prescribers hear most weeks is some version of: "my heart feels like it's racing, is that Wegovy?" The answer is: it can be, and it is a known and documented side effect. GLP-1 receptor agonists, including semaglutide, can cause a modest increase in resting heart rate, typically in the region of one to five beats per minute on average across trials. For most people this is clinically minor and settles with time, particularly as the body adjusts to each dose step.

Where it matters more is in people with pre-existing arrhythmias or heart failure. This is precisely why the consultation process reviews your full cardiac history rather than just your BMI. If you are already managing an irregular heart rhythm or have been told you have a reduced ejection fraction, that detail goes to the prescriber and shapes the decision. Palpitations that feel severe, persistent, or accompanied by chest pain or dizziness are always a reason to seek medical attention promptly, not to wait for your next check-in.

The full picture of how semaglutide affects heart rate and rhythm is covered in more detail on a dedicated page if you want to go deeper on the physiology.

Who should be cautious, and what the prescriber is weighing up

For most adults eligible for Wegovy under its licensed criteria (BMI of 30 or above, or 27 or above with a weight-related condition) the cardiovascular risk profile of the medicine is either neutral or favourable. Weight loss itself improves blood pressure, lipid levels and inflammatory markers, all of which benefit the heart over time.

Caution applies in specific circumstances. Anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) is excluded from treatment. People with severe heart failure or certain arrhythmias may need specialist input before a decision is made. Pregnancy is another situation where Wegovy is not recommended, the Wegovy and pregnancy page sets out what the guidance says.

There is also a liver dimension that occasionally surprises people: semaglutide has recently received UK conditional approval for a form of liver disease called MASH. If you are curious whether semaglutide is bad for your liver and what the current evidence shows, that question is explored in detail alongside the broader picture of how it interacts with liver health. You can read that evidence alongside this page.

The cost of treatment is a practical consideration too, and if that is on your mind, the Wegovy pricing page explains what private treatment typically involves without hidden fees.

The honest summary: protective, with caveats

The weight of published evidence, including a dedicated outcomes trial cited in NICE's guidance on semaglutide for weight management (TA875), does not support the idea that Wegovy is bad for your heart. In people with existing cardiovascular disease, it has demonstrated clear benefit. In people without it, it is not known to cause harm at a population level, and the improvements in weight, blood pressure and metabolic markers that accompany treatment generally favour cardiac health.

The caveats are real but specific: a temporary heart-rate nudge, particular contraindications in rare cardiac conditions, and the general principle that a prescription-only medicine should be taken under clinical supervision. None of those caveats make Wegovy dangerous for the heart in otherwise eligible adults. They make it a medicine that deserves proper assessment, which is what a consultation provides.

If you would like to explore treatment with a prescriber who can review your individual history, you can speak to our prescribers through a free consultation, reviewed the same working day by a GPhC-registered Independent Prescriber at nume.